Deutsche Bank AG restated their buy rating on shares of Shire PLC (LON:SHP) in a research report report published on Thursday, October 5th. Deutsche Bank AG currently has a GBX 5,700 ($75.74) price objective on the biopharmaceutical company’s stock.
A number of other brokerages also recently issued reports on SHP. Goldman Sachs Group, Inc. (The) dropped their price objective on shares of Shire PLC from GBX 6,800 ($90.35) to GBX 6,400 ($85.04) and set a conviction-buy rating on the stock in a report on Wednesday, June 28th. Liberum Capital restated a hold rating and set a GBX 4,900 ($65.11) target price on shares of Shire PLC in a research note on Wednesday, June 28th. Credit Suisse Group restated an outperform rating and set a GBX 5,350 ($71.09) target price on shares of Shire PLC in a research note on Tuesday, June 27th. Royal Bank Of Canada restated an outperform rating on shares of Shire PLC in a research note on Tuesday, June 27th. Finally, J P Morgan Chase & Co restated an overweight rating on shares of Shire PLC in a research note on Tuesday, June 27th. Four analysts have rated the stock with a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the company. Shire PLC currently has a consensus rating of Buy and a consensus target price of GBX 5,829.67 ($77.46).
Shire PLC (SHP) opened at 3821.50 on Thursday. The company has a 50-day moving average of GBX 3,872.21 and a 200 day moving average of GBX 4,244.95. The company’s market cap is GBX 34.64 billion. Shire PLC has a 52-week low of GBX 3,603.50 and a 52-week high of GBX 5,210.00.
TRADEMARK VIOLATION WARNING: “Shire PLC’s (LON:SHP) Buy Rating Reiterated at Deutsche Bank AG” was posted by BBNS and is owned by of BBNS. If you are reading this news story on another website, it was illegally stolen and reposted in violation of U.S. and international trademark & copyright law. The legal version of this news story can be read at https://baseballnewssource.com/markets/shire-plc-shp-earns-buy-rating-from-deutsche-bank-ag/1700188.html.
The business also recently announced a dividend, which will be paid on Friday, October 20th. Stockholders of record on Thursday, September 7th will be paid a dividend of GBX 3.85 ($0.05) per share. This represents a dividend yield of 0.1%. The ex-dividend date is Thursday, September 7th.
In other news, insider Anne Minto bought 190 shares of Shire PLC stock in a transaction on Friday, September 29th. The stock was acquired at an average cost of GBX 3,785 ($50.29) per share, for a total transaction of £7,191.50 ($9,555.54). Also, insider Flemming Ornskov bought 8,400 shares of Shire PLC stock in a transaction on Tuesday, August 22nd. The stock was purchased at an average price of GBX 3,665 ($48.70) per share, with a total value of £307,860 ($409,061.92).
Shire PLC Company Profile
Shire plc is a biotech company focused on serving people with rare diseases and other specialized conditions. The Company’s segment is engaged in research, development, licensing, manufacturing, marketing, distribution and sale of specialist medicines. It focuses its development resources on projects in various therapeutic areas (TAs), including Neuroscience, Ophthalmology, Hematology, Oncology, Immunology, Gastrointestinal (GI)/Metabolic/Endocrinology Diseases.
Receive News & Ratings for Shire PLC Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Shire PLC and related companies with our FREE daily email newsletter.